glp 1 news A wave of new #GLP1 drug options for type 2 #Diabetes and #Obesity was a major focus at #ADA2026. In the latest JAMA Medical podcast, Jennifer Abbasi interviews Rita Kalyani, MD Health insurer Cigna will stop

It is also an issue affecting patients who had started losing weight but then are not able to continue taking the medication and start to gain weight again, she says

People think they should be able to control this with willpower, he says

And as the buzz on these medications, especially semaglutide, grows louder, people are flocking to doctors or the black market to get their hands on them, even people who dont have obesity or diabetes

Accessed April 9, 2026.

Patients often report nausea, vomiting, bloating, or bowel changes early in treatment

As shortages of brand-name GLP-1 medications begin to ease, regulators are increasing scrutiny on these platforms to ensure patient safety and compliance, signaling a broader crackdown on unapproved or gray-market weight-loss treatments